Deutsche Bank AG decreased its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 45.4% in the fourth quarter, Holdings Channel reports. The fund owned 4,410 shares of the medical instruments supplier’s stock after selling 3,668 shares during the period. Deutsche Bank AG’s holdings in Mesa Laboratories were worth $917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently modified their holdings of the stock. Conestoga Capital Advisors LLC raised its stake in Mesa Laboratories by 2.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 486,256 shares of the medical instruments supplier’s stock worth $101,331,000 after acquiring an additional 10,817 shares during the last quarter. BlackRock Inc. raised its stake in Mesa Laboratories by 10.2% in the 4th quarter. BlackRock Inc. now owns 252,580 shares of the medical instruments supplier’s stock worth $52,634,000 after acquiring an additional 23,384 shares during the last quarter. Vanguard Group Inc. raised its stake in Mesa Laboratories by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 161,627 shares of the medical instruments supplier’s stock worth $30,000,000 after acquiring an additional 3,309 shares during the last quarter. Vanguard Group Inc raised its stake in Mesa Laboratories by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 161,627 shares of the medical instruments supplier’s stock worth $30,000,000 after acquiring an additional 3,309 shares during the last quarter. Finally, Ranger Investment Management L.P. raised its stake in Mesa Laboratories by 75.4% in the 4th quarter. Ranger Investment Management L.P. now owns 157,019 shares of the medical instruments supplier’s stock worth $32,721,000 after acquiring an additional 67,492 shares during the last quarter. Institutional investors own 72.57% of the company’s stock.
MLAB has been the subject of a number of research analyst reports. TheStreet upgraded Mesa Laboratories from a “c” rating to a “b-” rating in a research note on Friday, February 8th. ValuEngine upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Zacks Investment Research upgraded Mesa Laboratories from a “hold” rating to a “buy” rating and set a $256.00 target price for the company in a research note on Wednesday, April 3rd. BidaskClub lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, March 7th. Finally, Sidoti initiated coverage on Mesa Laboratories in a research note on Wednesday, March 13th. They issued a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $256.00.
In other Mesa Laboratories news, Director Evan Guillemin sold 1,746 shares of Mesa Laboratories stock in a transaction dated Wednesday, February 20th. The stock was sold at an average price of $232.31, for a total transaction of $405,613.26. Following the completion of the transaction, the director now owns 50,214 shares in the company, valued at approximately $11,665,214.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert V. Dwyer sold 5,575 shares of Mesa Laboratories stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $232.00, for a total value of $1,293,400.00. Following the transaction, the director now owns 53,913 shares of the company’s stock, valued at approximately $12,507,816. The disclosure for this sale can be found here. Insiders have sold a total of 8,005 shares of company stock valued at $1,856,333 in the last quarter. Company insiders own 15.00% of the company’s stock.
NASDAQ MLAB opened at $247.28 on Thursday. The stock has a market cap of $981.82 million, a price-to-earnings ratio of 40.03 and a beta of 0.37. Mesa Laboratories, Inc. has a fifty-two week low of $156.99 and a fifty-two week high of $263.27. The company has a quick ratio of 1.20, a current ratio of 1.57 and a debt-to-equity ratio of 0.25.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 31st will be paid a dividend of $0.16 per share. The ex-dividend date is Thursday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.26%. Mesa Laboratories’s payout ratio is currently 10.36%.
TRADEMARK VIOLATION WARNING: This news story was published by Highlight Press and is owned by of Highlight Press. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://highlightpress.com/2019/05/16/mesa-laboratories-inc-mlab-shares-sold-by-deutsche-bank-ag.html.
About Mesa Laboratories
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Featured Story: How to identify percentage decliners
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.